Updated on 29 November 2013
Singapore: Australia based Ascend Biopharmaceuticals has collaborated with 3M Drug Delivery Systems to evaluate 3M's Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend's proprietary cancer vaccine technology.
The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.
Under the terms of the agreement, 3M will provide access to the proprietary TLR7/8 agonist 3M-051 that will be chemically conjugated to Ascend's ASN platform - an antigen presenting, cell targeting and delivery technology that allows vaccine antigens and immune modulators to be selectively targeted to specialized antigen presenting cells.
An important feature of Ascend's targeting platform is its ability to efficiently enable cross presentation and to allow the generation of a strong cytotoxic CD8+ T cell response to a vaccine antigen in addition to a strong antibody response. Many earlier generations of cancer vaccines had a tendency to generate predominantly CD4+ T cell responses but only weak CD8+ T cell responses.
"Our research has demonstrated encouraging clinical and immunological responses and we believe the chemical conjugation of a potent TLR agonist could confer further improvements to the previously observed clinical responses," said Dr. Clement Leong, Ascend Biopharmaceuticals Chief Executive Officer. "The 3M TLR7/8 agonist 3M-051 is clearly a best-in-class compound, and we are particularly excited in exploiting this with our cancer vaccine platform."